Literature DB >> 846492

Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity.

P F Wright, K B Ross, J Thompson, D T Karzon.   

Abstract

To assess the impact of an influenza A/Port Chalmers infection on normal young children, we monitored 147 children during an epidemic; 121 were seronegative. There was a high attack rate (61 of 147), and a high rate of symptomatic disease (38 of 147), which resulted in frequent physician visits (25 of 38). Influenza accounted for 76 per cent of the sick-child visits during the two-month epidemic period. Young children undergoing primary influenza infection produced hemagglutination inhibition and antineuraminidase antibodies. Because of the immunologic responsiveness of young children, we examined the serologic correlates of protection. Ten children previously infected with influenza A/London and 16 who received live, attenuated A/Hong Kong ts-1[E] vaccine were protected against infection with the non-homologous A/Port Chalmers strain. The morbidity of influenza and ability of the young child to produce protective antibody should encourage evaluation of life, attenuated influenza vaccines in this age group.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 846492     DOI: 10.1056/NEJM197704142961501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  24 in total

1.  Surveillance of respiratory viral infections by rapid immunofluorescence diagnosis, with emphasis on virus interference.

Authors:  G Anestad
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

2.  Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts.

Authors:  Terho Heikkinen; Robert Booy; Magda Campins; Adam Finn; Per Olcén; Heikki Peltola; Carlos Rodrigo; Heinz-Josef Schmitt; Fabian Schumacher; Stephen Teo; Catherine Weil-Olivier
Journal:  Eur J Pediatr       Date:  2005-12-21       Impact factor: 3.183

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Towards better prescribing.

Authors:  R J Taylor
Journal:  J R Coll Gen Pract       Date:  1978-05

5.  Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.

Authors:  B R Murphy; M A Phelan; D L Nelson; R Yarchoan; E L Tierney; D W Alling; R M Chanock
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1), in Japanese adult volunteers.

Authors:  N Yamane; Y Nakamura; M Yuki; T Odagiri; N Ishida
Journal:  J Hyg (Lond)       Date:  1984-04

Review 7.  Innate sensors of influenza virus: clues to developing better intranasal vaccines.

Authors:  Takeshi Ichinohe; Akiko Iwasaki; Hideki Hasegawa
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

8.  Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge.

Authors:  T R Cate; R B Couch
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

9.  Antibody responses after inactivated influenza vaccine in young children.

Authors:  Peter F Wright; Edith Sannella; Jian R Shi; Yuwei Zhu; Mine R Ikizler; Kathryn M Edwards
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

10.  Outcome of influenza infection: effect of site of initial infection and heterotypic immunity.

Authors:  R A Yetter; S Lehrer; R Ramphal; P A Small
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.